Aparna Swaminathan

Assistant Professor of Medicine

Medicine, Pulmonary, Allergy, and Critical Care Medicine

aparna.swaminathan@duke.edu

DUMC 103000, Durham, NC 27710

Room 2077 MSRB II, 2 Genome Court, Durham, NC 27710

Menu

AT A GLANCE

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Embed Profile Data

Selected Grants

IM027-1015 BMS A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028

BMS IM027-068 IPF A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028

PHINDER GMS-PH-001

Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2023 - 2028

Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases (K23)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028

Clinetic Retrospective Registry Study (PI Initiated)

ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2024 - 2027

IM027-1015 BMS A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028

BMS IM027-068 IPF A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028

PHINDER GMS-PH-001

Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2023 - 2028

Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases (K23)

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028

Clinetic Retrospective Registry Study (PI Initiated)

ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2024 - 2027

PPF Retrospective Analysis (PPF)

ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2025

CHARACTERIZING THE ILD CARE CONTINUUM USING REAL-WORLD EVIDENCE

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2024